ALNY vs TECH: fair value comparison
Alnylam Pharmaceuticals, Inc. and Bio-Techne Corporation · Updated 2026-10-19
ALNY is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, TECH currently ranks higher by quality score.
| ALNY | TECH | |
|---|---|---|
| Verdict | Awaiting full valuation | Undervalued |
| Last price | $231.83 | $72.46 |
| 12-month range | $205.48–$481.59 | $43.30–$72.61 |
| Rank by discount to fair value | — | #42 of 108 Healthcare |
| Rank by quality score | #22 of 301 Healthcare | #20 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Uptrend |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: ALNY fair value analysis · TECH fair value analysis